J. Menezes

2.7k total citations · 1 hit paper
24 papers, 544 citations indexed

About

J. Menezes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, J. Menezes has authored 24 papers receiving a total of 544 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in J. Menezes's work include Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (10 papers) and Lung Cancer Treatments and Mutations (9 papers). J. Menezes is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (10 papers) and Lung Cancer Treatments and Mutations (9 papers). J. Menezes collaborates with scholars based in United States, Brazil and France. J. Menezes's co-authors include F. Stephen Hodi, Evan J. Lipson, Stéphane Dalle, Dirk Schadendorf, Georgina V. Long, Erika Castillo Gutiérrez, Paolo A. Ascierto, Luis Matamala, Piotr Rutkowski and Jean‐Jacques Grob and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

J. Menezes

24 papers receiving 533 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2

2024 37 citations Jeffrey D. Bradley, Shunichi Sugawara et al. ESMO Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Menezes United States	11	469	227	165	98	54	24	544
Coraline Duménil France	9	427 0.9×	235 1.0×	129 0.8×	124 1.3×	135 2.5×	20	545
Erika Rijavec Italy	7	305 0.7×	152 0.7×	80 0.5×	110 1.1×	79 1.5×	11	428
Nikita Patel United States	4	560 1.2×	133 0.6×	368 2.2×	72 0.7×	52 1.0×	10	667
A. Patel United States	5	445 0.9×	154 0.7×	267 1.6×	54 0.6×	40 0.7×	12	542
Audrey Hennequin France	11	410 0.9×	154 0.7×	195 1.2×	106 1.1×	81 1.5×	34	561
M-J. Ahn South Korea	14	517 1.1×	394 1.7×	105 0.6×	118 1.2×	93 1.7×	68	622
Zhuxing Chen China	8	231 0.5×	145 0.6×	108 0.7×	54 0.6×	47 0.9×	18	363
Meagan S. Barbee United States	6	232 0.5×	91 0.4×	82 0.5×	71 0.7×	21 0.4×	8	331
L. Bouhlel France	5	530 1.1×	397 1.7×	80 0.5×	52 0.5×	161 3.0×	7	621
Lucia Bonomi Italy	8	256 0.5×	220 1.0×	66 0.4×	113 1.2×	36 0.7×	23	433

Countries citing papers authored by J. Menezes

Since Specialization

Citations

This map shows the geographic impact of J. Menezes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Menezes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Menezes more than expected).

Fields of papers citing papers by J. Menezes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Menezes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Menezes. The network helps show where J. Menezes may publish in the future.

Co-authorship network of co-authors of J. Menezes

This figure shows the co-authorship network connecting the top 25 collaborators of J. Menezes. A scholar is included among the top collaborators of J. Menezes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Menezes. J. Menezes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lipson, Evan J., F. Stephen Hodi, Hussein Tawbi, et al.. (2025). Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. European Journal of Cancer. 225. 115547–115547. 1 indexed citations

Bochtler, Tilmann, A. Krämer, Chantal Pauli, et al.. (2024). 200P Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study. Annals of Oncology. 35. S296–S297. 1 indexed citations

Reck, Martin, Tudor–Eliade Ciuleanu, Michael Schenker, et al.. (2024). Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.. Journal of Clinical Oncology. 42(16_suppl). 8560–8560. 6 indexed citations

Tawbi, Hussein A., F. Stephen Hodi, Evan J. Lipson, et al.. (2024). Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047. Journal of Clinical Oncology. 43(13). 1546–1552. 24 indexed citations

Tawbi, Hussein A., F. Stephen Hodi, Evan J. Lipson, et al.. (2024). Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years.. Journal of Clinical Oncology. 42(16_suppl). 9524–9524. 7 indexed citations

Bourlon, María T., Laurence Albigès, Matías Chacón, et al.. (2024). Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial.. Journal of Clinical Oncology. 42(16_suppl). 4532–4532. 2 indexed citations

Bradley, Jeffrey D., Shunichi Sugawara, K.H. Lee, et al.. (2024). LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2. ESMO Open. 9. 102986–102986. 37 indexed citations breakdown →

Tawbi, Hussein A., F. Stephen Hodi, Evan J. Lipson, et al.. (2023). Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.. Journal of Clinical Oncology. 41(16_suppl). 9502–9502. 7 indexed citations

Mileshkin, Linda, Tilmann Bochtler, Chantal Pauli, et al.. (2023). LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP). Annals of Oncology. 34. S1254–S1255. 11 indexed citations

10.

Carbone, David P., Tudor–Eliade Ciuleanu, Michael Schenker, et al.. (2023). First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).. Journal of Clinical Oncology. 41(17_suppl). LBA9023–LBA9023. 6 indexed citations

11.

Paz‐Ares, Luis, Tudor–Eliade Ciuleanu, Manuel Cobo, et al.. (2022). First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.. Journal of Clinical Oncology. 40(17_suppl). LBA9026–LBA9026. 19 indexed citations

12.

Armstrong, Andrew J., Noel W. Clarke, Antoine Thiery-Vuillemin, et al.. (2022). Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial.. Journal of Clinical Oncology. 40(16_suppl). 5050–5050. 2 indexed citations

13.

Tawbi, Hussein A., F. Stephen Hodi, Evan J. Lipson, et al.. (2022). Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.. Journal of Clinical Oncology. 40(16_suppl). 9505–9505. 10 indexed citations

14.

Hodi, F. Stephen, Hussein A. Tawbi, Evan J. Lipson, et al.. (2021). 1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047. Annals of Oncology. 32. S867–S868. 4 indexed citations

15.

Reck, Martin, Tudor–Eliade Ciuleanu, Michael Schenker, et al.. (2021). OA03.02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA. Journal of Thoracic Oncology. 16(1). S2–S2. 1 indexed citations

16.

Reck, Martin, Tudor–Eliade Ciuleanu, Manuel Cobo, et al.. (2021). First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.. Journal of Clinical Oncology. 39(15_suppl). 9000–9000. 13 indexed citations

17.

Paz‐Ares, Luis, T-E. Ciuleanu, Manuel Cobo, et al.. (2021). 98O First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA. Journal of Thoracic Oncology. 16(4). S750–S751. 14 indexed citations

18.

Lipson, Evan J., Hussein Tawbi, Dirk Schadendorf, et al.. (2021). Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).. Journal of Clinical Oncology. 39(15_suppl). 9503–9503. 118 indexed citations

19.

Reck, Martin, T-E. Ciuleanu, Manuel Cobo, et al.. (2020). LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA. Annals of Oncology. 31. S1187–S1188. 5 indexed citations

20.

Reck, Martin, Tudor–Eliade Ciuleanu, Manuel Cobo, et al.. (2020). Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.. Journal of Clinical Oncology. 38(15_suppl). 9501–9501. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact